Efficacy of Bisphosphonate Treatment in Young Adults with Fragility Fractures
Overview
This population-based cohort study demonstrated that bisphosphonate therapy significantly reduces the risk of subsequent major osteoporotic fractures in premenopausal women with prior fragility fractures. Notably, ibandronate use and longer treatment durations were associated with greater fracture risk reductions.
Background
Osteoporosis leads to decreased bone density and increased fracture risk, commonly studied in older adults but also affecting young adults with fragility fractures. Treatment decisions in young adults are challenging due to limited evidence on bisphosphonate efficacy and concerns about long-term drug retention. While bisphosphonates are used off-label in pediatric conditions to improve bone density, data on fracture risk reduction in young adults remain scarce. This study aimed to evaluate bisphosphonate effectiveness in reducing fractures among premenopausal women with osteoporotic fractures.
Data Highlights
Parameter
Bisphosphonate Users (n=132)
Nonusers (n=396)
Hazard Ratio (95% CI)
Major Osteoporotic Fractures
Lower incidence
Reference
0.618 (0.396-0.963)
Ibandronate Users - Major Osteoporotic Fractures
Significant reduction
Reference
0.376 (0.164-0.861)
Ibandronate Users - Nonvertebral Fractures
Significant reduction
Reference
0.214 (0.052-0.877)
Bisphosphonate Use ≥180 days - Major Osteoporotic Fractures
Significant reduction
Reference
0.528 (0.300-0.929)
Bisphosphonate Use ≥180 days - Nonvertebral Fractures
Significant reduction
Reference
0.409 (0.187-0.895)
Key Findings
Bisphosphonate therapy reduced the risk of major osteoporotic fractures by approximately 38% compared to nonusers (HR 0.618).
Ibandronate specifically showed greater efficacy, reducing major osteoporotic fractures by 62% and nonvertebral fractures by 79%.
Longer bisphosphonate treatment duration (≥180 days) was associated with significantly lower fracture risks.
The study included 2087 premenopausal women with osteoporotic fractures, with 132 bisphosphonate users matched to 396 nonusers.
Propensity score matching was used to balance confounders such as age and BMI between groups.
Clinical Implications
Clinicians should consider bisphosphonate therapy for premenopausal women with a history of fragility fractures to reduce the risk of subsequent fractures. Ibandronate may offer enhanced fracture protection, and treatment duration of at least 180 days appears important for efficacy. These findings support more proactive management of young adults at high fracture risk.
Conclusion
Bisphosphonate treatment significantly lowers fracture risk in young premenopausal women with prior osteoporotic fractures, particularly with ibandronate use and longer treatment duration. This evidence supports incorporating bisphosphonates into treatment strategies for this population.
References
National Health Insurance Service-National Sample Cohort Study, 2003-2014 -- Bisphosphonate Efficacy in Young Adults
